ClinicalTrials.gg
Not yet recruitingNCT07300709Updated Dec 24, 2025

Renal Histopathology and Transcriptomic Analysis in Hepatorenal Syndrome During Liver Transplantation

An interventional study of renal biopsy in Hepatorenal Syndrome, Liver Regeneration, AKI - Acute Kidney Injury and Liver Transplant, sponsored by The University of Hong Kong. Not yet recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by The University of Hong Kong · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Hepatorenal Syndrome (HRS) is a serious complication that can occur in patients with liver cirrhosis, characterised by kidney dysfunction, or acute kidney failure (AKI). While it has traditionally been thought that HRS affects structurally normal kidneys and is completely reversible with liver transplantation, recent evidence suggests this may not always be the case.

The purpose of this study is to examine the actual structural changes in the kidneys of patients with HRS through tissue biopsy and advanced molecular analysis. This may help us better understand the disease mechanism and potentially improve treatment approaches. We aim to challenge the current understanding that HRS always occurs in structurally normal kidneys and is always reversible after liver transplantation. This study will provide valuable insights into the pathophysiology of HRS and may lead to improved diagnostic and treatment strategies in the future.

This is a 3-year single center prospective, non-randomised, open label study at Queen Mary Hospital, The University of Hong Kong. All consecutive patients accepted on the liver transplant waiting list will be invited to participate. Patient will undergo several procedures related to liver transplant and kidney assessment, and receive liver transplantation and renal biopsy.

02

Conditions studied

  • Hepatorenal Syndrome, Liver Regeneration
  • AKI - Acute Kidney Injury
  • Liver Transplant

Keywords

  • Hepatorenal syndrome
  • HRS
  • HRS AKI
  • acute kidney injury
  • liver transplant
  • renal biopsy
  • renal histopathology
  • transcriptomics
03

In context

Hepatorenal Syndrome

50 studies on the registry are indexed under Hepatorenal Syndrome; 7 are open to participants now.

This study's planned enrollment of 42 is below the median of 50 across 36 interventional studies indexed under Hepatorenal Syndrome.

Browse Hepatorenal Syndrome studies →

Lead sponsor

The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be able to understand and provide
  2. Age ≥ 18 years of age at time of study entry
  3. Accepted for liver transplantation (LT)
  4. Fulfill the diagnostic criteria of HRS AKI according to International Club of Ascites (ICA) guidelines

3-month post transplant renal inclusion criteria:

  1. Patient with adequate intraoperative renal biopsy
  2. Patient must be able to understand and provide informed consent

Exclusion criteria

Exclusion Criteria:

  1. Inability or unwillingness to give written
  2. Patient with known pre-existing renal disease
  3. Patient with solitary kidney
  4. Re-transplantation
  5. ABO-incompatible LT
  6. Fail to provide 3-month post transplant renal

3-month post transplant renal biopsy exclusion criteria:

  1. Graft failure after LT
  2. Any condition deemed inappropriate by the PI
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Renal biopsy

    To examine the actual structural changes in kidneys of patients with HRS through tissue biopsy and advanced molecular analysis, and hope that may help us better understand the disease mechanism and potentially improve treatment approaches

    Procedure: renal biopsy

Interventions

  • Procedurerenal biopsy

    To examine the actual structural changes in kidneys of patients with HRS through tissue biopsy and advanced molecular analysis, and hope that may help us better understand the disease mechanism and potentially improve treatment approaches

06

What researchers measure

Primary outcomes

  1. Proportion of patients with HRS AKI

    Proportion of patients with HRS AKI who have normal, reversible or permanent injury on renal histopathology

    Time frame: up to 3 years

  2. Histopathological changes

    Histopathological changes and their association with clinical parameters

    Time frame: up to 3 years

Secondary outcomes

  1. Duration of HRS AKI

    Incidence and duration of HRS AKI

    Time frame: up to 3 years

  2. Response to standard treatment (Terlipressin and albumin)

    Response to standard treatment (Terlipressin and albumin)

    Time frame: up to 3 years

  3. Perioperative morbidity

    Perioperative morbidity including need and duration for renal replacement therapy

    Time frame: up to 3 years

  4. Post-transplant renal recovery rates

    Post-transplant renal recovery rates

    Time frame: up to 3 years

  5. Transcriptomic signature differences

    Transcriptomic signature differences between HRS AKI and non-HRS AKI patients

    Time frame: up to 3 years

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Aug 2028, 31 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Dec 24, 2025
StartEst.
Jan 1, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Dec 2028
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07300709
Responsible party
Dr. Tiffany Cho-Lam Wong (Clinical Associate Professor, The University of Hong Kong) — Principal investigator
First posted
Dec 24, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Dec 24, 2025

Study contacts

Tiffany Wong
Contact
wongtcl@hku.hk
+852 22553025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion